All In Biotech

Drug Trial Radar · NCT03549871

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis

ATLAS-PPX: an Open-label, Multinational, Switching Study to Describe the Efficacy and Safety of Fitusiran Prophylaxis in Patients With Hemophilia A and B Previously Receiving Factor or Bypassing Agent Prophylaxis.

Last checked: Nov 19, 2026Latest source record: Feb 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

80

Actual

Start

Jul 25, 2018

Primary completion

Jan 20, 2022

Study completion Mar 25, 2022

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jun 8, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To characterize the frequency of bleeding episodes (BE) while receiving fitusiran treatment, relative to the frequency of bleeding episodes while receiving factor concentrate or bypassing agent (BPA) prophylaxis. Secondary Objectives: * To characterize the following while receiving fitusiran treatment, relative to receiving factor or BPA prophylaxis: * the frequency of spontaneous bleeding episodes * the frequency of joint bleeding episodes * health related quality of life (HRQOL) in participants greater than or equal to (\>=) 17 years of age * To characterize the frequency of bleeding episodes during the onset and treatment periods in participants receiving fitusiran. * To characterize the safety and tolerability of fitusiran. * To characterize the annualized weight-adjusted consumption of factor/BPA while receiving fitusiran treatment, relative to receiving factor or BPA prophylaxis.

Conditions

  • Hemophilia

Interventions

  • FitusiranDrug

    Pharmaceutical form: solution for injection Route of administration: subcutaneous

  • BPA prophylaxisDrug

    Pharmaceutical form: solution for injection Route of administration: Intravenous

  • Factor (FVIII or FIX) prophylaxisDrug

    Pharmaceutical form: solution for injection Route of administration: Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimated Annualized Bleeding Rate (ABR)Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
  2. Observed Annualized Bleeding Rate (ABR)Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest

Locations

35 sites in 15 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 0139

    Los Angeles, California

  • Investigational Site Number 6104

    Prahran, Australia

  • Investigational Site Number 8604

    Beijing, China

  • Investigational Site Number 4501

    Copenhagen, Denmark

  • Investigational Site Number 3303

    Lyon, France

  • Investigational Site Number 5301

    Crumlin, Ireland

  • Investigational Site Number 9701

    Ramat Gan, Israel

  • Investigational Site Number 3902

    Milan, Italy

  • Investigational Site Number 8101

    Nagoya, Japan

  • Investigational Site Number 8102

    Nishinomiya, Japan

  • Investigational Site Number 8104

    Saitama, Japan

  • Investigational Site Number 8109

    Tokyo, Japan

  • Investigational Site Number 6004

    Ampang, Malaysia

  • Investigational Site Number 6002

    Johor Bahru, Malaysia

  • Investigational Site Number 6003

    Kota Kinabalu, Malaysia

  • Investigational Site Number 5201

    San Pablo, Mexico

  • Investigational Site Number 8201

    Busan, South Korea

  • Investigational Site Number 8202

    Daejeon, South Korea

  • Investigational Site Number 8204

    Seoul, South Korea

  • Investigational Site Number 9002

    Adana, Turkey (Türkiye)

  • Investigational Site Number 9001

    Ankara, Turkey (Türkiye)

  • Investigational Site Number 9004

    Antalya, Turkey (Türkiye)

  • Investigational Site Number 9008

    Gaziantep, Turkey (Türkiye)

  • Investigational Site Number 9005

    Istanbul, Turkey (Türkiye)

  • Investigational Site Number 9010

    Izmir, Turkey (Türkiye)

  • Investigational Site Number 9003

    Izmir, Turkey (Türkiye)

  • Investigational Site Number 9009

    Kayseri, Turkey (Türkiye)

  • Investigational Site Number 9006

    Samsun, Turkey (Türkiye)

  • Investigational site number 9013

    Van, Turkey (Türkiye)

  • Investigational Site Number 8003

    Kyiv, Ukraine

  • Investigational Site Number 8002

    Lviv, Ukraine

  • Investigational Site Number 4402

    Glasgow, United Kingdom

  • Investigational Site Number 4407

    London, United Kingdom

  • Investigational Site Number 4403

    London, United Kingdom

  • Investigational Site Number 4401

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.